Patent application number | Description | Published |
20130166819 | SYSTEMS AND METHODS OF LOADING DATA FROM A NON-VOLATILE MEMORY TO A VOLATILE MEMORY - A method may be performed in a data storage device that includes a controller, a non-volatile memory, and a volatile memory. The method includes loading a first portion of stored data from the non-volatile memory to the volatile memory according to one or more load priority indicators accessible to the controller. The method further includes, in response to completion of the loading of the first portion of the stored data to the volatile memory and prior to completion of loading a second portion of the stored data to the volatile memory, sending a signal to indicate to a host device operatively coupled to the data storage device that the volatile memory is ready for use by the host device. | 06-27-2013 |
20130166864 | SYSTEMS AND METHODS OF PERFORMING A DATA SAVE OPERATION - A method includes determining, based on an indication from a host device operatively coupled to a data storage device that includes a controller, a non-volatile memory including a hibernate area, a volatile memory, a non-volatile memory interface, and a volatile memory interface, that the data storage device is to enter a low-power state. The method includes, in response to determining that the data storage device is to enter a low-power state, performing a data save operation. The data save operation bypasses the non-volatile memory interface and the volatile memory interface and copies data from the volatile memory of the data storage device to the hibernate area of the non-volatile memory of the data storage device. | 06-27-2013 |
20130166866 | SYSTEMS AND METHODS OF PERFORMING A DATA SAVE OPERATION - A method includes entering a hibernation mode in a data storage device with a controller, a non-volatile memory, and a volatile memory having a first portion and a second portion. The hibernation mode is entered by copying, to the second portion, data that is in the first portion and that is flagged to remain available at the volatile memory during the hibernation mode, and powering off the first portion while maintaining power to the second portion. | 06-27-2013 |
20130166932 | SYSTEMS AND METHODS OF EXITING HIBERNATION IN RESPONSE TO A TRIGGERING EVENT - A method may be performed by an electronic device coupled to a volatile system memory. The method includes entering a hibernation mode of the electronic device, where in the hibernation mode, the volatile system memory is powered off. The method further includes detecting a triggering event and, in response to detecting the triggering event, exiting the hibernation mode. While exiting the hibernation mode, the volatile system memory is powered and a pre-hibernation state of the volatile system memory is restored. | 06-27-2013 |
Patent application number | Description | Published |
20080248092 | Formulations of Water Insoluble or Poorly Water Soluble Drugs in Lipidated Glycosaminoglycan Particles and Their Use for Diagnostic and Therapy - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery. | 10-09-2008 |
20100267814 | Targeting MicroRNAs for the Treatment of Liver Cancer - Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis. | 10-21-2010 |
20110251150 | Targeting MicroRNAs For The Treatment Of Liver Cancer - Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis. | 10-13-2011 |
20120171261 | FORMULATIONS OF WATER INSOLUBLE OR POORLY WATER SOLUBLE DRUGS IN LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE FOR DIAGNOSTICS AND THERAPY - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery. | 07-05-2012 |
20120295962 | TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER - Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis. | 11-22-2012 |
20130289098 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER - The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described. | 10-31-2013 |
20140206854 | TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER - Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis. | 07-24-2014 |
20150031751 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER - The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described. | 01-29-2015 |
Patent application number | Description | Published |
20120072198 | COUPLING ARCHITECTURAL AND IMPLEMENTATION/BEHAVIORAL MODELS OF A COMPUTER-BASED SYSTEM - Coupling architectural and implementation/behavioral models of a computer-based system by creating a bridge element, defining a port of the bridge element, associating the port of the bridge element with a port of an implementable element of an architectural model of a computer-based system and a port of an implementation element of an implementation/behavioral model of the computer-based system, mapping an interface member of the implementation element port to an interface member of the implementable element port, generating, from a template, skeleton source code applicable for the mapped interface member, generating a usage description element for the architectural model corresponding to the mapped interface member, generating an architectural description document from the architectural model, generating implementation code from the implementation/behavioral model and the generated skeleton source code, and generating a declaration file for an operating system service for use by the implementation code. | 03-22-2012 |
20130211810 | COUPLING ARCHITECTURAL AND IMPLEMENTATION/BEHAVIORAL MODELS OF A COMPUTER-BASED SYSTEM - Coupling architectural and implementation/behavioral models of a computer-based system by creating a bridge element, defining a port of the bridge element, associating the port of the bridge element with a port of an implementable element of an architectural model of a computer-based system and a port of an implementation element of an implementation/behavioral model of the computer-based system, mapping an interface member of the implementation element port to an interface member of the implementable element port, generating, from a template, skeleton source code applicable for the mapped interface member, generating a usage description element for the architectural model corresponding to the mapped interface member, generating an architectural description document from the architectural model, generating implementation code from the implementation/behavioral model and the generated skeleton source code, and generating a declaration file for an operating system service for use by the implementation code. | 08-15-2013 |